Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its FDA-approved therapy.

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Efforts to develop off-the-shelf (OTS) cell therapies are accelerating across global biotech, as researchers aim to make next ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the importance of long-term monitoring. A recent study reveals CAR T-cell therapy ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...